Zalain 300 mg ovule

Dosage

Children: Refer to specific drug information for detailed dosage recommendations.

Adults: Refer to specific drug information for detailed dosage recommendations.

Mechanism of action

The mechanism of action varies depending on the specific drug that 'contains' certain active ingredients. Each compound will have its own unique pharmacological pathway and target within the body, which can include receptor modulation, enzyme inhibition, or other biochemical interactions.

Pharmacodynamics

Pharmacodynamics will depend on the active ingredients in the formulation. It generally encompasses the biochemical and physiological effects of the drug and its mechanisms of action, including the relationship between drug concentration and effect.

Pharmacokinetics

Pharmacokinetics involves the absorption, distribution, metabolism, and excretion of the specific active ingredients within the formulation. This can vary significantly based on the drug's chemical properties, route of administration, and individual patient factors.

Pregnancy

Consult with a healthcare provider before use, as safety during pregnancy has not been established.

Breast-feeding

Consult with a healthcare provider before use, as it is not known if this drug is excreted in human milk.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Vaginal candidiasis (yeast infections)
• Bacterial vaginosis
• Hormonal replacement therapy
• Contraception
• Endometrial hyperplasia

Dosage

Children: Dosage for paediatric patients depends on the condition being treated and the formulation used. Consult specific guidelines for paediatric dosing.

Adults: Dosage varies based on the specific active ingredient and indication. Refer to product-specific guidelines for dosing.

Mechanism of action

The mechanism of action of ovules depends on their active ingredients. For example, antifungal ovules work by disrupting the cell membrane of fungi, leading to cell death. Hormonal ovules may act by delivering estrogen or progesterone directly to the vaginal tissue, influencing local and systemic hormonal environments.

Pharmacodynamics

Pharmacodynamics varies with the active component of the ovule. Antifungals may show fungicidal or fungistatic activity depending on the concentration, while hormonal agents can modulate local tissue responses, influencing cellular growth and function in the vaginal epithelium.

Pharmacokinetics

Pharmacokinetics of ovules is influenced by the formulation and the specific active ingredient. Generally, after insertion, the ovule dissolves and releases its active substances, which are absorbed locally through the vaginal mucosa. Systemic absorption may occur for certain hormonal treatments, leading to systemic effects. The onset of action can vary based on the type of medication used.

Pregnancy

Consult a healthcare professional before use. The safety of ovules during pregnancy is not well established, and risks should be evaluated against potential benefits.

Breast-feeding

Consult a healthcare professional before use. The effects of ovules on breastfeeding infants are not well studied.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Superficial fungal infections
• Tinea pedis (athlete's foot)
• Tinea cruris (jock itch)
• Tinea corporis (ringworm)
• Candidiasis

Dosage

Children: Refer to the BNF for Children for appropriate dosing information.

Adults: Apply a thin layer of sertaconazole cream to the affected area twice daily for 2 to 4 weeks, or as directed by a healthcare professional.

Mechanism of action

Sertaconazole interacts with 14-alpha demethylase, a cytochrome P-450 enzyme necessary for converting lanosterol to ergosterol, a vital component of fungal cell membranes. Inhibition of ergosterol synthesis increases cellular permeability, leading to leakage of cellular contents. Additionally, sertaconazole may inhibit endogenous respiration, interact with membrane phospholipids, inhibit yeast transformation to mycelial forms, and impair triglyceride and phospholipid biosynthesis.

Pharmacodynamics

Sertaconazole is a highly selective inhibitor of fungal cytochrome P-450 sterol C-14 alpha-demethylation, essential for fungal cell wall synthesis. This leads to the accumulation of toxic 14-alpha-methyl sterols in fungi and results in fungistatic effects. It demonstrates activity against pathogens such as Cryptococcus neoformans and Candida species, showing efficacy in both normal and immunocompromised models of systemic infections.

Pharmacokinetics

Sertaconazole is well absorbed through topical applications, with minimal systemic absorption. The pharmacokinetics of sertaconazole in humans have not been extensively studied. The drug is metabolized by liver enzymes, primarily through oxidation and conjugation processes, and is excreted mainly in the urine. Due to its low systemic absorption, significant drug interactions are unlikely.

Adverse effects

• Local irritation
• Erythema
• Pruritus
• Burning sensation

Precautions

• Use with caution in patients with a history of hypersensitivity to imidazole or triazole antifungals.
• Avoid contact with eyes and mucous membranes.

Pregnancy

Sertaconazole should only be used in pregnancy if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Caution is advised when administering sertaconazole to nursing mothers, as it is not known if it is excreted in human milk.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Formulations

• Cream
• Solution

Mechanism of action

Sertaconazole interacts with 14-α demethylase, a cytochrome P-450 enzyme necessary to convert lanosterol to ergosterol. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Sertaconazole may also inhibit endogenous respiration, interact with membrane phospholipids, inhibit the transformation of yeasts to mycelial forms, inhibit purine uptake, and impair triglyceride and/or phospholipid biosynthesis.

Pharmacodynamics

Sertaconazole is an imidazole/triazole type antifungal agent. Sertaconazole is a highly selective inhibitor of fungal cytochrome P-450 sterol C-14 &alpha;-demethylation via the inhibition of the enzyme cytochrome P450 14&alpha;-demethylase. This enzyme converts lanosterol to ergosterol, and is required in fungal cell wall synthesis. The subsequent loss of normal sterols correlates with the accumulation of 14 &alpha;-methyl sterols in fungi and may be partly responsible for the fungistatic activity of fluconazole. Mammalian cell demethylation is much less sensitive to fluconazole inhibition. Sertaconazole exhibits <i>in vitro</i> activity against <i>Cryptococcus neoformans</i> and <i>Candida spp.</i> Fungistatic activity has also been demonstrated in normal and immunocompromised animal models for systemic and intracranial fungal infections due to <i>Cryptococcus neoformans</i> and for systemic infections due to Candida albicans.